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ABSTRACT 
Background and Aims: People who have recently injected drugs are a priority population in efforts 
to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of 
people with recent injecting drug use living with HCV, and the proportion of people with recent 
injecting drug use among all people living with HCV infection at global, regional, and country-levels. 
Methods: Data from a global systematic review of injecting drug use and HCV antibody prevalence 
among people with recent (previous year) injecting drug use were used to estimate the prevalence 
and number of people with recent injecting drug use living with HCV. These data were combined 
with a systematic review of global HCV prevalence to estimate the proportion of people with recent 
injecting drug use among all people living with HCV. 
Results: There are an estimated 6.1 million [95% uncertainty interval (UI) 3.4-9.2] people with recent 
injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI 31.6-
47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI 1.0-2.1), Eastern Europe 
(1.5 million, UI 0.7-2.4), and North America (1.0 million, UI 0.4-1.7). People with recent injecting drug 
use comprise an estimated 8.5% (UI 4.6-13.1) of all HCV infections globally, with the greatest 
proportions in North America (30.5%, UI 11.7-56.7), Latin America (22.0%, UI 15.3-30.4), and Eastern 
Europe (17.9%, UI 8.2-30.9).  
Conclusions: Although globally about forty percent of people with recent injecting drug use are living 
with hepatitis C virus (HCV) and almost nine percent of all HCV infections globally occur among 
people with recent injecting drug use, there is wide variation among countries and regions.   
Funding: National Drug and Alcohol Research Centre, UNSW Sydney; Australian National Health and 
Medical Research Council; John C Martin Foundation. 
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INTRODUCTION 
 
The World Health Organization (WHO) has set a goal to eliminate hepatitis C virus (HCV) as a global 
public health threat by 2030 (1). Between 2015 and 2030, WHO targets include reducing new HCV 
infections by 80%, the number of HCV deaths by 65%, and increasing HCV diagnoses from 20% to 
90% and eligible persons receiving HCV treatment from <5% to 80%. People who inject drugs 
represent a priority population for HCV elimination, given the high prevalence and incidence in this 
group (2-7).  
 
We previously estimated the global, regional, and country-level prevalence of HCV (viraemic  
infections) (8). In 2015, the global prevalence of HCV infection was estimated to be 1.0% (95% 
uncertainty interval 0.8–1.1), corresponding to 71.1 million (62.5–79.4) people living with HCV (8). 
We also estimated the global, regional, and country-level HCV antibody prevalence among people 
with recent injecting drug use (previous 12 months). Among the estimated 15.6 million [uncertainty 
intervals (UI) 10.2-23.7 million] people with recent injecting drug use aged 15-64 years globally, it is 
estimated that 52.3% (UI 42.4-62.1%) are HCV-antibody positive, representing 8.2 million people 
who have recently injected drugs (UI 4.7-12.4 million) with past or present HCV (7). Given that 25% 
of people spontaneously clear HCV infection (9), estimates are needed on the prevalence and 
numbers of people with recent injecting drug use who are living with HCV infection (viraemic 
infection).   
 
There are no previous estimates at the global, regional, and country-levels of the HCV RNA 
(Ribonucleic acid) prevalence among people with recent injecting drug use, the number of people 
with recent injecting drug use who are living with HCV infection (HCV RNA detectable or viraemic), 
or the proportion of people with recent injecting drug use among all people living with HCV 
infection. These data are crucial to monitor progress of global HCV elimination efforts and identify 
high-burden settings to enable appropriate targeting of prevention and treatment strategies to 
achieve the WHO HCV targets. 
 
The aim of this study was to estimate the global HCV RNA prevalence (viraemic infections) among 
people who have recently injected drugs; the numbers of people with recent injecting drug use living 
with HCV infection; and the proportion of people who have recently injected drugs among all people 
living with HCV at global, regional, and country-levels.  
 
METHODS 
 
Study design and procedures 
This analysis utilized data from two published studies. The first study was a systematic review to 
estimate the number of people with recent injecting drug use and the HCV antibody (anti-HCV) 
prevalence among people who have recently (previous 12 months) injected drugs (10). The second 
study was a systematic review and modelling study to estimate the global viraemic HCV prevalence 
(8).  
 
The first systematic review estimated global, regional, and country-level prevalence of injecting drug 
use among people aged 15–64 years; and the prevalence of HIV, HCV, and hepatitis B virus (HBV) 
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among people with recent injecting drug use in 2015 (7). This review was performed consistent with 
the GATHER and PRISMA guidelines. Multiple search strategies (7) were used to identify papers and 
reports published since previous reviews of IDU prevalence (from 2008) (11) and of HCV amongst 
PWID (from 2011) (12). Without language restrictions, peer-reviewed databases (MEDLINE, Embase, 
and PsycINFO), and grey literature were systematically searched, and data requests disseminated to 
international experts and agencies. We searched for data on IDU prevalence, and the prevalence of 
HIV, HCV, and HBV among people with recent injecting drug use. Eligible data on prevalence of IDU, 
HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates 
were available, pooled for each country via random effects meta-analysis. Data on HCV RNA 
prevalence among people with recent injecting drug use were also extracted. Global, regional, and 
country-level estimates of the HCV antibody (anti-HCV) prevalence among people with recent 
injecting drug use were used for the current study (7).  
 
The second systematic review estimated global, regional, and country-levels viraemic HCV 
prevalence in 2015 (8). Data published between January 1, 2000 and March 31, 2016 were identified 
through searches of electronic peer-reviewed literature databases, PubMed and Embase (8). Non-
indexed government reports, personal communication with country experts, and additional studies 
identified through manual searches of references noted in publications were included where better 
data were not available. Articles were scored on the degree to which they could be extrapolated to 
the general population, the sample size, and the year of analysis. A Microsoft Excel-based (version 
2007) Markov-type model was populated with the highest-scoring epidemiological data for each 
country, used to estimate HCV prevalence over time (including in 2015). A Delphi process was used 
to gain country expert consensus and validate inputs. Further details of data extraction, scoring of 
data sources, Delphi process, and modelling, have been published (8). Global, regional, and country-
level estimates of the numbers of people with viraemic HCV infection were used for the current 
study (7). 
 
Statistical Analysis 
First, we sought to estimate the prevalence of viraemic HCV infection (detectable HCV RNA) among 
people with recent injecting drug use at global, regional, and country-levels. As shown in Table 1, 
48% (98 of 206) of countries had available data on HCV antibody prevalence among people with 
recent injecting drug use (n=374 studies) as compared to only 9% (19 of 206) of countries with 
available data on HCV RNA prevalence among people with recent injecting drug use (n=32 studies). 
Compared to studies of HCV antibody prevalence among people with recent injecting drug use 
(n=374), studies of HCV RNA prevalence among people with recent injecting (n=32), were less often 
estimate grade A (multi-site seroprevalence study with >1 sample types) (6.3% vs. 21.9%) and 
national samples (20.6% vs. 6.2%). Given the poor availability of data on HCV RNA prevalence, we 
sought to estimate the HCV viraemic proportion (those living with HCV infection) by using estimates 
of the prevalence of HCV antibodies among people with recent injecting drug use within each 
country (7) and multiplying by an estimate of the proportion developing viraemic HCV infection (9). 
The proportion with viraemic HCV infection among those who were HCV antibody positive [75%; 
95% confidence interval (CI) 71%, 79%] was estimated using data from a well-characterized merged 
dataset of nine international cohorts of people who had recently injected drugs who had acquired 
acute HCV infection and were followed prospectively for spontaneous HCV clearance and viraemic 
infection (9). The number of people with recent injecting drug use with viraemic HCV infection was 
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then estimated by multiplying the number of people with recent injecting drug use by the HCV 
viraemic prevalence.  
 
95% uncertainty intervals (UI) were estimated using Monte Carlo simulation taking 100,000 draws. A 
binomial distribution was used because the parameters of interest were proportions (product of IDU 
proportion among population and HCV proportion among PWID). Estimated sample sizes were 
derived based on the 95% CIs and standard errors of proportion estimates in each country. The 
simulated UIs incorporated the uncertainty of estimates.  
 
Following the collation of country-specific estimates, estimates of regional and global viraemic HCV 
infection among people with recent injecting drug use were derived. Region-specific, weighted 
estimates of the prevalence of HCV were made using all the observed estimates and 95% CI of 
estimates in each country within that region and deriving a weighted estimate and UI taking into 
account country population size. Regional estimates were then used to estimate the global 
prevalence.  
 
The proportion of people with recent injecting drug use among all people living with HCV infection 
was computed by dividing the total number of people with recent injecting drug use living with HCV 
by the total number of all people living with HCV for countries where both estimates were available. 
As above, 95% UIs were simulated taking 100,000 draws carrying forward the standard errors for 
both people with recent injecting drug use living with HCV and the total HCV viraemic infection 
prevalence estimates. 
 
RESULTS 
 
Sufficient data were identified to enable estimates of the HCV viraemic prevalence among people 
with recent injecting drug use in 98 countries, and to estimate the population size of people with 
recent injecting drug use living with HCV in 76 countries. Sufficient data were identified to enable 
estimates of the number of people living with HCV overall in 98 countries. There were sufficient data 
to estimate the number of people with recent injecting drug use as a proportion of all people living 
with HCV in 55 countries. 
 
Results are shown by region in Table 2 and by country in Table 3. Globally, we estimate that in 2015, 
39.2% (UI 31.6-47.0) of people with recent injecting drug use have HCV viraemic infection, 
representing 6.1 million (UI 3.4-9.2) people with recent injecting drug use living with HCV infection 
globally. Of the 71.1 million (UI 62.5-79.4 million) people living with HCV infection (Table 2), we 
estimate that 8.5% (UI 4.6-13.1) are people with recent injecting drug use (Table 2). 
 
At the regional level, HCV viraemic prevalence among people with recent injecting drug use varied 
from 16.3% (UI 12.7-20.1) in Sub-Saharan Africa to 48.6% (UI 42.0-55.2) in Eastern Europe (Table 2). 
The largest estimated numbers of people with recent injecting drug use living with HCV infection 
were in East and Southeast Asia (1.5 million, UI 1.0-2.1), Eastern Europe (1.5 million, UI 0.7-2.4), and 
North America (1.0 million, UI 0.4-1.7). The proportion of people with recent injecting drug use 
among all people living with HCV infection ranged from 1.5% (UI 0.7-2.4) in the Middle East and 
North Africa to 30.5% (UI 11.7-56.7) in North America (Table 2). Regions with people with recent 
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injecting drug use comprising >10% of all people living with HCV infection included Latin America 
(22.0%, UI 15.3-30.4), Eastern Europe (17.9%, UI 8.2-30.9), Australasia (17.7%, UI 12.1-25.2), 
Caribbean (16.7%, 8.9-30.6), and Western Europe (17.2%, UI 9.9-30.4).  
 
At the country-level, there was very marked variation in the estimates of HCV viraemic prevalence 
between countries, ranging from 0.5% (UI 0.0-1.4; Maldives) to 72.8% (UI 68.8-76.7; Mauritius) 
[Figure 1 and Table 3]. The HCV viraemic prevalence was 60–80% in 10 countries, 40-<60% in 38 
countries, and <40% in 50 countries. The largest populations of people with recent injecting drug use 
living with HCV infection were in Russia (969,500; UI 463,000-1,570,500), the United States (895,000; 
UI 353,500-1,601,500), China (828,000; UI 493,000, 1,228,500), and Brazil (461,000, UI 336,500-
596,500) [Figure 2 and Table 3]; together, these countries accounted for 51% of people with recent 
injecting drug use living with HCV infection. The top 25 countries accounting for 82% of all people 
with recent injecting drug use living with HCV infection globally are shown in Figure 3.  The 
proportion of people with recent injecting drug use among all people living with HCV infection varied 
between 0.9% (UI 0.4-3.0; India) and 46.6% (UI 22.1-100.0; Commonwealth of Puerto Rico) [Figure 4 
and Table 3]. The proportion of people with recent injecting drug use among all people living with 
HCV infection was <10% in 21 countries, >10-<20% in 11 countries, and >20% in 23 countries.  
 
DISCUSSION 
 
This study estimated that there are 6.1 million (UI 3.4-9.2) people with recent injecting drug use 
living with HCV infection worldwide, comprising 8.5% (UI 4.6-13.1) of all HCV infections globally. 
There was considerable variation in the prevalence of HCV infection among people with recent 
injecting drug use at regional and country-levels, and in the proportion of all HCV infection that is 
among people with recent injecting drug use. These findings highlight countries and regions where a 
focus on HCV prevention and treatment among people with recent injecting drug use will be 
required, if HCV elimination targets are to be met.  
 
The greatest numbers of people with recent injecting drug use living with HCV infection are in 
Eastern Europe, East and Southeast Asia, and North America. Half of all people with recent injecting 
drug use living with HCV infection are from just four countries: the Russian Federation, the United 
States, China, and Brazil. Further, the top 25 countries account for 82% of all people with recent 
injecting drug use living with HCV infection globally. Although PWID are a critical population for HCV 
elimination in many settings, concerted efforts to increase access to prevention and treatment for 
people with recent injecting drug use in these countries will be pivotal to the success of global HCV 
elimination efforts. Key among these will be harm reduction measures to prevent incident infections 
(13), and increased testing, linkage to care and uptake of directly-acting antiviral therapy among 
people with recent injecting drug use (14, 15). 
 
Countries or territories where it is estimated that at least one-third of people living with HCV 
infection are people with recent injecting drug use include Georgia, Austria, Finland, Malaysia, and 
Puerto Rico. In a further 16 countries, at least one-quarter of people living with HCV infection are 
people with recent injecting drug use. However, there are also 21 countries where the proportion of 
people living with HCV are people with recent injecting drug use is <10%. Collectively, these data 
highlight the variation in the proportion of overall viraemic HCV infection occurring among people 
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with recent injecting drug use globally, reflecting the differing epidemiology of HCV in different 
settings. As such, different types of prevention, testing, and treatment strategies will be needed to 
address HCV elimination targets according to the epidemiology within a given country. It should also 
be noted that there were 124 countries and territories where injecting drug use is known to occur, 
but no data were available to assess the proportion of people with HCV infection who are people 
with recent injecting drug use.  
 
This study was limited to estimates among people with recent injecting drug use and will not include 
those who have even ‘temporarily’ or permanently ceased injecting. As such, this study 
underestimates the proportion of infections that occur among people who inject drugs within an 
overall epidemic, given that some infections due to injecting drug use will be among people with a 
history of injecting who have ceased injecting. It is critical to consider people who have recently 
injected drugs as well as those who have ceased injecting in the design of strategies to address HCV. 
 
There are several limitations to this study. The search may have missed some literature (particularly 
grey literature), despite our wide scope of online searchers and requests for information from 
people across many countries. To address this possibility, we liaised with the WHO, Global Fund, 
UNODC and UNAIDS staff to contact experts within countries and obtain reports that were not 
available online. However, we doubt that any missed papers will alter these findings in a meaningful 
fashion. 
 
Errors may have been made in data extraction and interpretation. To reduce such errors, all sources 
and data from which the final estimates were derived were double-checked by at least two 
reviewers prior to inclusion with a further round prior to finalisation with a third reviewer. We have 
online interactive presentations of these data at [URL to be provided] to ensure full transparency and 
to increase the potential for people to interact with the estimates and results, and suggest additional 
data sources. We encourage feedback at global.reviews@unsw.edu.au.  
 
Although the review team searched for publications in multiple languages, we may have missed 
documents in languages in which we are not fluent. Those with access to data or papers/reports in 
other languages should contact us. It is also important to acknowledge a number of features of our 
approach to synthesis and imputation of estimates, driven by the gaps in data available. Although 
there has been a clear increase in efforts to quantify the extent of IDU and HCV among PWID, there 
are still major gaps in data in some regions. A hierarchical grading system was used to evaluate 
estimates based on geographical generalisability (e.g., from multiple sites) and across various 
populations of PWID (e.g., treatment and non-treatment samples). Exclusion of estimates based on a 
study’s methodology grade was only applied to estimates of IDU and anti-HCV prevalence. 
Nonetheless, our recent approach, which involved pooling estimates, and our more sophisticated 
approach to estimating uncertainty around all our estimates, including our method of estimating 
uncertainty around imputed estimates, are both improvements upon previous reviews. 
 
A limitation is the lack of country-level data to estimate the viraemic HCV prevalence (98 countries), 
numbers of people living with HCV (76 countries) and the proportion among the overall population 
living with HCV among people with recent injecting drug use (55 countries). Data were sparse in 
regions such as the Caribbean, Latin America, Pacific Island States & Territories, Sub Saharan Africa, 
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and the Middle East and North Africa. The estimates for these regions should be interpreted with 
caution and highlights that further work is needed to improve estimates in countries from these 
regions. 
 
In this study, data on HCV antibody prevalence [multiplied by an estimate of the proportion of 
people with HCV antibodies who would have active viraemia, 0.75 (95% CI, 0.71, 0.79)] was used to 
estimate the viraemic HCV prevalence, instead of actual data on HCV RNA prevalence. We opted for 
this approach because the data on HCV antibody prevalence was of higher quality and coverage, and 
there were few countries for which any data were available for HCV RNA (Table 1). Instead, we used 
data on the estimated viraemic prevalence from a well-defined series of nine prospective cohorts of 
acute HCV infection among people who inject drugs with well-characterized events of spontaneous 
clearance (9). Although this provides a very accurate estimate of the proportion who progress to 
viraemic infection, the limitation is that this approach may have either over-estimated or under-
estimated the true prevalence of viraemic infection in people with recent injecting drug use in 
various settings. In some regions, increased reinfection risk and/or higher HIV prevalence may result 
in a higher viraemic prevalence and our approach may have underestimated the viraemic prevalence 
(16). Conversely, it is known that some factors (e.g. female sex) increase spontaneous clearance and 
can reduce the viraemic prevalence, which might have overestimated the viraemic prevalence 
observed. Also, these analyses did not take into consideration clearance due to HCV treatment, 
which might have led to an overestimation of the prevalence and numbers of people with recent 
injecting drug use living with HCV infection. However, this is also unlikely to have affected these 
estimates as uptake of HCV treatment among PWID was very low prior to 2015 (17-21). This study 
clearly demonstrates the need to integrate HCV RNA testing into future studies of HCV among 
people with recent injecting drug use to enable the evaluation of viraemic HCV RNA prevalence to 
improve national, regional and global estimates, particularly given that larger numbers of PWID are 
initiating HCV treatment (and will be anti-HCV positive, but HCV RNA negative).  
 
Denominator data are also subject to limitations. General population data may be in error for some 
countries where accurate census data are lacking. Population sizes of people with recent injecting 
drug use were based on the best available empirical estimates for each country, but there is often 
considerable uncertainty around estimates of this population, which translates to uncertainty in 
estimates of the number of PWID with HCV infection and the proportion of HCV infections occurring 
among people with recent injecting drug use. Estimates of HCV viraemia in people with recent 
injecting drug use incorporated the uncertainties in the IDU population size, anti-HCV prevalence 
estimate, and viraemia multiplier. However, estimates of the prevalence of recent IDU and of HCV 
prevalence both in people with recent injecting drug use and in the general population are subject to 
biases, which may be responsible for some estimates that do not seem correct. Further, the 
extracted data was often from a single year and changes in injecting drug user populations and HCV 
incidence could not be measured. This highlights the importance of continuing to improve country-
level estimates of people with recent injecting drug use and those with viraemic HCV infection.  
 
Irrespective of these limitations, this review advances our understanding of HCV prevalence and 
disease burden among people with recent injecting drug use. Accurate estimates of the prevalence 
and burden of viraemic HCV infection among people with recent injecting drug use are crucial to 
guide policy and practice and guide the development of strategies to enhance testing, linkage to 
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care and treatment in this population. This review highlights that concerted efforts will be required 
in countries with large numbers of people infected with HCV to achieve global HCV elimination 
among PWID. Further, it highlights that strategies to achieve a reduction in HCV burden will need to 
be tailored to the individual country, based on the HCV epidemiology and the proportion of overall 
infections occurring in people with recent injecting drug use. Collectively, these data will inform 
mathematical modelling to identify strategies to increase diagnosis, treatment and reduce the 
number of new infections to achieve HCV elimination at a country level. Further work is needed to 
better understand the population size of people with a history of injecting drug use and the 
prevalence of viraemic HCV infection and burden in those with former, but not recent, injecting drug 
use.  
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Table 1: Quality of evidence of countries with available HCV antibody prevalence and HCV RNA 
prevalence data among recent PWID 
 
HCV antibody 
prevalence among 
recent PWID 
(n=374) 
HCV RNA prevalence 
among recent PWID  
(n=32)  
Countries with available 
data 
98/206 (47.6%) 19/206 (9.2%) 
Estimate grade*   
    A                           82 (21.9%) 2 (6.3%) 
    B1                  225 (60.2%) 20 (62.5%) 
    B2   13 (3.6%) 1 (3.1%) 
    C 54 (14.4%) 8 (25.0%) 
    U - 1 (3.1%) 
Geographic coverage   
    National sample                      77 (20.6%) 2 (6.2%) 
    Sub-national sample  87 (23.3%) 11 (34.4%) 
    City sample 210 (56.1%) 19 (59.4%) 
Literature type#   
    A1 128 (34.2%) 30 (93.75%) 
    A2               4 (1.1%) - 
    B2   147 (39.3%) - 
    B3 81 (21.7%) - 
    C   8 (2.2%) 2 (6.25%) 
    D 6 (1.6%) - 
 
*Grading for estimate grade: A - Multi-site seroprevalence study with >1 sample types (e.g. needle-
syringe programmes, drug treatment centres, incarcerated IDUs), B1 - Seroprevalence study, single 
sample type and multiple sites; B2 - Seroprevalence study, multiple sample types and a single site; C 
- Seroprevalence study, single sample type; D - Registration or notification of cases of hepatitis/HIV 
infection; E - Prevalence study using self-reported hepatitis/HIV status; Ungraded - Estimate with 
methodology unknown. #Grading for literature type: A1 - Peer-reviewed journal article; A2 - Abstract 
of published article only; B1 - Published book/report/monograph from scholarly or commercial 
publisher;B2 - Published book/report/monograph from international governmental or monitoring 
organisation (e.g. UN, WHO, EMCDDA); B3 - Published book/report/monograph from other source 
(e.g. Government, NGO, university, research centre); C - Conference abstract; D - Other unpublished 
report (incl. Website downloads); E  - Email and private correspondence; F – ARQ.  
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Table 2: Regional and global estimates of the prevalence of HCV viraemic infection among people 
with recent injecting drug use, the number of people with recent injecting drug use living with HCV 
viraemic infection, the total population living with HCV vireamic infection and the proportion of 
people with recent injecting drug use among the total population with HCV viraemic infection 
 
 
Prevalence of 
HCV viraemic 
infection 
among people 
with recent 
injecting drug 
use 
% (UI) 
Number of people with 
recent injecting drug 
use living with HCV 
viraemic infection 
(UI) 
 
 
Total population living 
with HCV viraemic 
infection  
(UI) 
Proportion 
of people 
with recent 
injecting 
drug use 
among the 
total 
population 
with HCV 
viraemic 
infection 
% (UI) 
Eastern Europe 48.6 (42.0, 
55.2) 
1,466,500 (699,500, 
2,377,000) 
8,181,000 (6,304,000, 
8,250,000) 
17.9 (8.2, 
30.9) 
Western Europe 39.9 (35.7, 
44.1) 
402,500 (264,500, 
557,000) 
2,347,000 (1,969,000, 
3,289,000) 
17.2 (9.9, 
30.4) 
East and Southeast 
Asia 
37.7 (28.2, 
47.5) 
1,506,000 (1,019,500, 
2,078,500) 
16,313,000 (12,636,000, 
17,242,000) 
9.2 (5.8, 
13.8) 
South Asia 28.9 (13.4, 
47.5) 
296,000 (114,500, 
518,000) 
15,617,500 (13,341,000, 
20,182,000) 
1.9 (0.7, 3.6) 
Central Asia 40.5 (36.5, 
44.5) 
114,000 (69,000, 
165,000) 
2,516,000 (2,010,000, 
2,749,000) 
4.5 (2.6, 6.9) 
Caribbean 47.6 (40.2, 
55.1) 
37,500 (22,500, 55,000) 225,500 (183,000, 315,000) 16.7 (8.9, 
30.6) 
Latin America 46.4 (43.1, 
49.8) 
846,000 (617,500, 
1,092,500) 
3,854,000 (3,131,000, 
3,948,000) 
22.0 (15.3, 
30.4) 
North America 40.5 (29.2, 
51.7) 
960,000 (398,000, 
1,679,500) 
3,148,000 (2,429,000, 
4,034,000) 
30.5 (11.7, 
56.7) 
Pacific Island states & 
terr1 
41.4 (32.4, 
50.5) 
9,000 (5,500, 14,000) 117,500 (101,000, 376,000) 7.9 (1.9, 
11.1) 
Australasia 42.8 (38.9, 
46.8) 
49,500 (35,500, 65,000) 278,500 (220,000, 297,000) 17.7 (12.1, 
25.2) 
Sub-Saharan Africa 16.3 (12.7, 
20.1) 
225,000 (45,500, 
458,500) 
9,83,500 (7,605,000, 
15,112,000) 
2.3 (0.5, 5.9) 
Middle East & North 
Africa 
36.1 (29.2, 
43.2) 
126,000 (65,000, 
199,500) 
8,625,500 (6,838,000, 
9,155,000) 
1.5 (0.7, 2.4) 
Global 39.2 (31.6, 
47.0) 
6,063,500 (3,434,500, 
9,246,000) 
71,146,000 (62,472,000, 
79,404,000) 
8.5 (4.6, 
13.1) 
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Notes: 
PWID – people who inject drugs; HCV - Hepatitis C virus; UI - uncertainty interval (see methods for 
details of estimation). 
Number of people with recent injecting drug use with viraemic HCV infection are rounded to the 
nearest 500. 
Total population number with viraemic HCV infection are rounded to the nearest 1,000. 
1. Note that no estimates of the prevalence of anti-HCV among people who inject drugs have 
been located for the Pacific Islands and Territories, so the weighted observed global 
prevalence was used here. Considerable caution should be used with these estimates. 
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Table 3: Country-level estimates of the prevalence of HCV viraemic infection among people with 
recent injecting drug use, the number of people with recent injecting drug use living with HCV 
viraemic infection, the total population living with HCV vireamic infection and the proportion of 
people with recent injecting drug use among the total population with HCV viraemic infection 
Region and 
country 
Prevalence 
of HCV 
viraemic 
infection 
among 
people with 
recent 
injecting 
drug use 
% (UI) 
Number of people with 
recent injecting drug use 
living with HCV viraemic 
infection 
(UI) 
Total population living 
with HCV viraemic 
infection  
 (UI) 
Proportion of 
people with 
recent 
injecting drug 
use among 
the total 
population 
with HCV 
viraemic 
infection 
% (UI) 
Eastern Europe     
Armenia                             
32.0 
(22.0,42.3) 4,000 (1,500, 8,500) 
NK 
NG 
Azerbaijan                          
46.6 
(34.9,58.0) 20,000 (14,000, 27,000) 
190,000 (125,000, 212,000) 10.6 
(7.3,17.3) 
Belarus                             
43.7 
(32.3,55.1) 18,000 (7,000, 31,500) 
NK 
NG 
Bosnia & 
Herzegovina                
30.0 
(20.7,39.5) NK 
NK 
NK 
Bulgaria                            
51.5 
(47.3,55.8) 9,500 (7,500, 11,500) 
87,000 (46,000, 112,000) 11.0 
(6.9,20.4) 
Czech Republic                      
13.7 
(10.9,16.7) 6,500 (5,000, 8,000) 
43,000 (22,000, 48,500) 15.0 
(9.2,28.6) 
Estonia                             
59.4 
(49.8,68.4) 5,000 (2,500, 8,500) 
18,000 (11,500, 20,000) 28.2 
(12.6,53.0) 
Georgia 
51.8 
(42.9,60.5) 59,500 (12,500, 119,500) 
165,000 (120,000, 169,000) 36.1 
(7.4,76.9) 
Hungary                             
35.0 
(22.9,47.2) 1,500 (500, 2,500) 
52,500 (28,500, 55,500) 
2.7 (1.1,5.6) 
Latvia                              
55.8 
(49.8,61.7) 8,000 (6,000, 10,000) 
43,000 (28,000, 50,000) 18.1 
(11.8,29.1) 
Lithuania                           
30.8 
(28.1,33.7) 1,500 (500, 2,500) 
32,500 (20,000, 38,500) 
4.5 (2.0,8.6) 
Moldova                             
37.5 
(25.5,49.7) 4,500 (2,500, 7,000) 
NK 
NG 
Poland                           
44.0 
(40.5,47.6) NK 
184,000 (136,000, 224,000) 
NK 
Romania                             62.9 51,000 (36,000, 67,500) 547,000 (397,000, 566,000) 9.3 (6.0,14.2) 
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Region and 
country 
Prevalence 
of HCV 
viraemic 
infection 
among 
people with 
recent 
injecting 
drug use 
% (UI) 
Number of people with 
recent injecting drug use 
living with HCV viraemic 
infection 
(UI) 
Total population living 
with HCV viraemic 
infection  
 (UI) 
Proportion of 
people with 
recent 
injecting drug 
use among 
the total 
population 
with HCV 
viraemic 
infection 
% (UI) 
(58.7,67.0) 
Russian 
Federation                       
51.6 
(44.2,58.9) 
969,500 (463,000, 
1,570,500) 
4,748,000 (3,238,000, 
4,960,000) 
20.4 
(9.6,37.2) 
Slovakia                            
42.1 
(26.6,57.7) 8,500 (3,500, 14,500) 
33,000 (20,000, 37,500) 25.4 
(9.6,52.0) 
Ukraine 
40.4 
(36.3,44.6) 129,000 (54,000, 222,000) 
NK 
NG 
Western Europe     
Albania 25.5 
(20.1,31.1) 1,500 (1,000, 2,500) 
NK 
NG 
Andorra NK NK NK NK 
Austria 45.7 
(40.6,50.9) 8,500 (6,000, 11,500) 
21,000 (6,000, 30,500) 40.2 
(20.1,100.0) 
Belgium 43.8 
(34.9,52.6) 11,500 (7,000, 16,500) 
64,500 (23,000, 75,500) 17.8 
(8.7,45.8) 
Croatia                             
27.5 
(21.0,34.2) 1,500 (1,000, 2,500) 
26,000 (16,500, 28,500) 
6.7 (4.0,11.3) 
Denmark 31.9 
(26.8,37.2) 5,500 (4,000, 6,500) 
19,500 (14,500, 19,500) 27.2 
(18.8,39.5) 
England 23.1 
(20.0,26.3) 48,500 (41,500, 56,000) 
168,000 (91,000, 211,000) 28.9 (18.8, 
51.8) 
Finland 55.2 
(51.2,59.4) 9,500 (7,000, 12,500) 
22,500 (16,000, 26,000) 41.6 
(27.4,62.8) 
France  48.0 
(44.5,51.5) 39,500 (31,500, 47,500) 
194,000 (92,500, 222,000) 20.2 
(12.4,40.1) 
FYR (Form. Yug. 
Rep) Macedonia 
46.6 
(43.4,49.9) 2,500 (1,500, 3,000) 
NK 
NK 
Germany 48.7 
(44.6,53.0) 64,000 (13,500, 129,000) 
205,000 (90,000, 313,000) 31.3 
(6.2,80.6) 
Greece 49.2 
(45.4,53.1) 2,500 (2,000, 3,000) 
132,000 (82,000, 169,000) 
1.9 (1.2,3.1) 
Greenland -- -- NK -- 
Iceland 47.3 NK 1,000 (1,000, 1,000) NK 
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Region and 
country 
Prevalence 
of HCV 
viraemic 
infection 
among 
people with 
recent 
injecting 
drug use 
% (UI) 
Number of people with 
recent injecting drug use 
living with HCV viraemic 
infection 
(UI) 
Total population living 
with HCV viraemic 
infection  
 (UI) 
Proportion of 
people with 
recent 
injecting drug 
use among 
the total 
population 
with HCV 
viraemic 
infection 
% (UI) 
(43.8,50.8) 
Ireland 56.0 
(52.5,59.4) 5,000 (3,500, 6,000) 
29,500 (20,000, 42,500) 16.2 
(10.0,28.9) 
Italy 43.4 
(38.8,48.1) 148,500 (98,500, 205,000) 
680,000 (455,000, 
1,641,000) 
21.8 
(7.6,33.9) 
Liechtenstein -- -- NK -- 
Luxembourg 61.0 
(55.9,66.1) 1,500 (1,000, 1,500) 
5,500 (3,500, 6,000) 25.2 
(16.6,41.1) 
Malta 18.9 
(10.4,28.4) NK 
1,000 (1,000, 1,500) 
NK 
Monaco NK NK NK NK 
Montenegro 32.6 
(29.4,35.9) NK 
NK 
NK 
Netherlands 41.5 
(36.7,46.3) 1,500 (1,000, 2,000) 
16,500 (5,000, 25,500) 
8.3 (4.2,22.9) 
Northern Ireland NK NK NK NK 
Norway 48.6 
(44.5,52.8) 4,000 (3,500, 5,000) 
21,000 (15,000, 24,500) 19.4 
(13.8,28.1) 
Portugal 65.8 
(59.1,72.2) 10,500 (9,000, 12,000) 
89,000 (74,000, 120,000) 11.7 
(8.2,18.1) 
San Marino NK NK NK NK 
Scotland 39.1 
(33.8,44.5) 6,000 (5,000, 7,500) 
NK 
NG 
Serbia 19.4 
(16.5,22.6) 5,500 (4,500, 7,000) 
NK 
NG 
Slovenia 22.9 
(19.6,26.2) 1,500 (1,000, 2,000) 
6,500 (4,500, 7,000) 21.3 
(13.3,33.5) 
Spain 53.3 
(50.2,56.3) 5,500 (2,000, 9,500) 
386,000 (202,000, 620,000) 
1.4 (0.5,3.6) 
Sweden 61.3 
(57.6,64.9) 5,000 (<500, 20,000) 
37,500 (28,000, 43,500) 13.3 
(0.0,46.6) 
Switzerland 55.9 
(51.0,60.9) 7,500 (6,000, 9,500) 
78,000 (45,500, 87,000) 
9.7 (6.3,16.7) 
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Region and 
country 
Prevalence 
of HCV 
viraemic 
infection 
among 
people with 
recent 
injecting 
drug use 
% (UI) 
Number of people with 
recent injecting drug use 
living with HCV viraemic 
infection 
(UI) 
Total population living 
with HCV viraemic 
infection  
 (UI) 
Proportion of 
people with 
recent 
injecting drug 
use among 
the total 
population 
with HCV 
viraemic 
infection 
% (UI) 
Wales 20.1 
(17.2,23.0) NK 
NK 
NK 
East and South 
East Asia 
 
   
Brunei 
Darussalam                   NK NK 
NK 
NK 
Cambodia                            NK NK 257,000 (147,000, 272,000) NK 
China                               
32.3 
(20.8,44.3) 
828,000 (493,000, 
1,228,500) 
9,795,000 (6,675,000, 
10,832,000) 8.5 (4.6,14.3) 
Indonesia 66.9 
(62.2,71.5) 
127,500 (103,000, 
153,000) 
1,289,000 (443,000, 
2,046,000) 9.9 (5.5,24.9) 
Japan                               
48.6 
(40.8,56.3) 
179,000 (130,500, 
234,500) 
857,000 (364,000, 
1,024,000) 
20.9 
(11.7,46.5) 
Lao PDR                             NK NK NK NK 
Malaysia                            
50.3 
(46.2,54.5) 
142,000 (116,000, 
169,500) 
382,000 (240,000, 405,000) 37.1 
(25.2,59.2) 
Mongolia                            NK NK 194,000 (131,000, 237,000) NK 
Myanmar                             
22.2 
(19.9,24.5) 38,500 (25,500, 53,000) 
NK 
NG 
North Korea                           -- -- NK -- 
Philippines                         
26.4 
(12.8,41.6) 6,500 (3,000, 11,500) 
614,000 (353,000, 651,000) 
1.1 (0.4,2.3) 
Republic of Korea                   
36.3 
(31.7,41.0) NK 
231,000 (148,000, 261,000) 
NK 
Singapore                           
31.9 
(28.9,35.0) NK 
NK 
NK 
Taiwan 68.2 
(64.4,72.0) NK 
489,000 (310,000, 877,000) 
NK 
Thailand                            
66.4 
(60.6,71.9) 34,000 (12,500, 60,000) 
463,000 (255,000, 487,000) 
7.4 (2.6,16.1) 
Timor Leste                         NK NK NK NK 
Viet Nam                            
43.8 
(31.8,55.7) 70,500 (47,000, 98,000) 
1,066,000 (580,000, 
1,116,000) 6.6 (3.7,12.5) 
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Region and 
country 
Prevalence 
of HCV 
viraemic 
infection 
among 
people with 
recent 
injecting 
drug use 
% (UI) 
Number of people with 
recent injecting drug use 
living with HCV viraemic 
infection 
(UI) 
Total population living 
with HCV viraemic 
infection  
 (UI) 
Proportion of 
people with 
recent 
injecting drug 
use among 
the total 
population 
with HCV 
viraemic 
infection 
% (UI) 
South Asia     
Afghanistan 28.4 
(20.7,36.3) 39,500 (23,000, 60,000) 
183,000 (85,000, 258,000) 21.5 
(10.5,46.9) 
Bangladesh 25.4 
(16.9,34.4) 17,500 (11,500, 24,000) 
NK 
NG 
Bhutan NK NK NK NK 
India 30.0 
(25.2,34.9) 59,000 (38,000, 84,000) 
6,245,000 (4,748,000, 
10,957,000) 0.9 (0.4,3.0) 
Iran 33.1 
(21.4,45.2) 52,000 (29,500, 81,000) 
199,000 (129,000, 226,000) 26.2 
(13.2,47.0) 
Maldives 0.5 (0.0,1.4) <500 (<500,<500) NK NG 
Nepal 33.4 
(23.1,43.8) 12,000 (8,000, 15,500) 
NK 
NG 
Pakistan 27.4 
(0.0,60.6) 116,000 (<500, 173,500) 
7,172,000 (5,363,000, 
7,487,000) 1.6 (0.7,3.6) 
Sri Lanka NK NK NK NK 
Central Asia     
Kazakhstan                          
44.1 
(39.8,48.4) 49,500 (30,000, 71,500) 
508,000 (334,000, 572,000) 
9.8 (5.4,16.7) 
Kyrgyzstan                          
32.9 
(29.9,36.0) 9,500 (5,500, 13,500) 
NK 
NG 
Tajikistan 46.0 
(41.9,50.2) 11,000 (6,500, 15,500) 
NK 
NG 
Turkmenistan                       NK NK NK NK 
Uzbekistan 38.8 
(34.7,43.0) 36,500 (22,500, 53,000) 
1,292,000 (902,000, 
1,524,000) 2.8 (1.6,4.6) 
Caribbean     
Antigua & 
Barbuda -- -- 
NK 
-- 
Bahamas                             NK NK NK NK 
Barbados -- -- NK -- 
Bermuda                                NK NK NK NK 
Comm. of Puerto 58.8 16,500 (10,000, 24,000) 35,500 (23,000, 60,500) 46.6 
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Region and 
country 
Prevalence 
of HCV 
viraemic 
infection 
among 
people with 
recent 
injecting 
drug use 
% (UI) 
Number of people with 
recent injecting drug use 
living with HCV viraemic 
infection 
(UI) 
Total population living 
with HCV viraemic 
infection  
 (UI) 
Proportion of 
people with 
recent 
injecting drug 
use among 
the total 
population 
with HCV 
viraemic 
infection 
% (UI) 
Rico (53.9,63.7) (22.1,100.0) 
Cuba                                -- -- 35,000 (13,500, 77,000) -- 
Dominica                            -- -- NK -- 
Dominican 
Republic                  NK NK 
68,000 (41,500, 108,000) 
NK 
Grenada                             -- -- NK -- 
Haiti                               NK NK NK NK 
Jamaica                             NK NK NK NK 
Saint Kitts & Nevis -- -- NK -- 
Saint Lucia -- -- NK -- 
St Vincent & the 
Grenadines -- -- 
NK 
-- 
Trinidad & Tobago -- -- NK -- 
Latin America     
Argentina 41.0 
(37.5,44.4) 33,000 (30,000, 36,000) 
326,000 (144,000, 490,000) 10.1 
(6.3,21.0) 
Belize -- -- NK -- 
Bolivia NK NK NK NK 
Brazil 47.9 
(44.3,51.5) 
461,000 (336,500, 
596,500) 
1,787,000 (1,293,000, 
1,896,000) 
25.8 
(17.2,38.5) 
Chile NK NK 56,500 (31,000, 94,000) NK 
Colombia 21.6 
(19.3,24.0) NK 
409,000 (272,000, 436,000) 
NK 
Costa Rica NK NK NK NK 
Ecuador NK NK NK NK 
El Salvador NK NK NK NK 
Guatemala NK NK NK NK 
Guyana NK NK NK NK 
Honduras NK NK NK NK 
Mexico 71.5 
(67.3,75.5) 107,500 (70,500, 149,000) 
532,000 (304,000, 557,000) 20.2 
(11.4,37.2) 
Nicaragua NK NK NK NK 
Panama NK NK 12,500 (7,500, 13,500) NK 
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Region and 
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Prevalence 
of HCV 
viraemic 
infection 
among 
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recent 
injecting 
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% (UI) 
Number of people with 
recent injecting drug use 
living with HCV viraemic 
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(UI) 
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with HCV viraemic 
infection  
 (UI) 
Proportion of 
people with 
recent 
injecting drug 
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the total 
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with HCV 
viraemic 
infection 
% (UI) 
Paraguay 7.4 (5.8,9.0) NK NK NK 
Peru NK NK 167,000 (99,000, 182,000) NK 
Suriname NK NK NK NK 
Uruguay 16.4 
(14.1,18.9) 1,000 (<500, 2,500) 
NK 
NG 
Venezuela NK NK 118,000 (58,500, 126,000) NK 
North America     
Canada 52.9 
(44.5,61.2) 65,000 (50,000, 82,000) 
212,000 (136,000, 246,000) 30.7 
(20.2,49.3) 
United States 39.8 
(28.4,51.3) 
895,000 (353,500, 
1,601,500) 
2,936,000 (2,231,000, 
3,826,000) 
30.5 
(10.9,58.9) 
Pacific Island 
States & Terr. 
 
   
American Samoa NK NK NK NK 
Fed. States of 
Micronesia NK NK 
NK 
NK 
Fiji NK NK 500 (<500, 3,000) NK 
French Polynesia NK NK NK NK 
Guam NK NK NK NK 
Kiribati NK NK NK NK 
Marshall Islands NK NK NK NK 
Nauru -- -- NK -- 
New Caledonia NK NK NK NK 
Northern Mariana 
Islands NK NK 
NK 
NK 
Palau NK NK NK NK 
Papua New 
Guinea NK NK 
94,500 (70,500, 328,000) 
NK 
Samoa NK NK <500 (<500, <500) NK 
Solomon Islands NK NK NK NK 
Tonga NK NK NK NK 
Tuvalu -- -- NK -- 
Vanuatu NK NK NK NK 
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Australasia     
Australia                           
40.1 
(36.9,43.5) 37,500 (27,500, 48,500) 
230,000 (178,000, 244,000) 16.2 
(11.1,23.2) 
New Zealand                         
53.9 
(46.8,61.1) 12,000 (8,000, 16,500) 
48,500 (30,000, 62,500) 25.0 
(14.7,42.9) 
Sub Saharan 
Africa 
 
   
Angola NK NK NK NK 
Benin NK NK NK NK 
Botswana -- -- NK -- 
Burkina Faso NK NK 247,000 (189,000, 256,000) NK 
Burundi NK NK 120,000 (93,000, 459,000) NK 
Cameroon NK NK 164,000 (117,000, 184,000) NK 
Cape Verde NK NK NK NK 
Central African 
Republic -- -- 
15,500 (11,000, 17,500) 
-- 
Chad NK NK 162,000 (111,000, 184,000) NK 
Comoros -- -- NK -- 
Congo (Kinshasa) NK NK NK NK 
Cote d'Ivoire 1.3 (0.0,7.1) <500 (<500, <500) NK NG 
Djibouti NK NK NK NK 
Equatorial Guinea -- -- NK -- 
Eritrea -- -- NK -- 
Ethiopia NK NK 647,000 (410,000, 726,000) NK 
Gabon NK NK 124,000 (90,000, 129,000) NK 
Gambia NK NK 17,000 (10,000, 27,000) NK 
Ghana 30.1 
(25.8,34.4) NK 
399,000 (305,000, 944,000) 
NK 
Guinea NK NK NK NK 
Guinea-Bissau -- -- NK -- 
Kenya 12.3 
(7.4,17.7) 4,000 (1,000, 7,500) 
115,000 (42,500, 126,000) 
3.3 (0.7,5.2) 
Lesotho -- -- NK -- 
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Liberia NK NK NK NK 
Madagascar 4.2 (1.8,7.0) 500 (<500, 3,000) 56,000 (39,000, 81,000) 1.2 (0.0,5.1) 
Malawi NK NK NK NK 
Mali NK NK NK NK 
Mauritania -- -- NK -- 
Mauritius 72.8 
(68.8,76.7) 5,000 (1,500, 9,500) 
NK 
NG 
Mozambique 50.3 
(46.2,54.4) 14,500 (<500, 31,000) 
NK 
NG 
Namibia -- -- NK -- 
Niger NK NK NK NK 
Nigeria 
4.3 (2.1,6.8) NK 
2,553,000 (1,902,000, 
2,651,000) NK 
Rep. of the Congo -- -- NK -- 
Rwanda NK NK NK NK 
Sao Tome & 
Principe -- -- 
NK 
-- 
Senegal 29.5 
(22.9,36.3) NK 
NK 
NK 
Seychelles 31.5 
(27.2,36.0) 500 (500, 500) 
NK 
NG 
Sierra Leone NK NK NK NK 
Somalia NK NK NK NK 
South Africa NK NK 356,000 (227,000, 441,000) NK 
Swaziland NK NK NK NK 
Togo NK NK NK NK 
Uganda NK NK NK NK 
United Rep.  of 
Tanzania 
20.8 
(16.4,25.4) 71,500 (41,000, 108,000) 
NK 
NG 
Zambia NK NK NK NK 
Zimbabwe NK NK NK NK 
Middle East & 
North Africa 
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Algeria NK NK 388,000 (140,000, 674,000) NK 
Bahrain NK NK 17,000 (11,000, 17,500) NK 
Cyprus 37.3 
(32.9,41.8) <500 (<500, <500) 
NK 
NG 
Egypt 37.1 
(26.7,47.5) NK 
5,625,000 (4,007,000, 
6,044,000) NK 
Iraq NK NK 85,500 (60,500, 96,500) NK 
Israel 34.0 
(28.3,39.9) NK 
100,000 (60,000, 103,000) 
NK 
Jordan NK NK 24,500 (10,500, 29,000) NK 
Kuwait NK NK NK NK 
Lebanon 17.6 
(10.5,25.2) NK 
7,500 (3,000, 18,000) 
NK 
Libyan Arab 
Jamahiriya 
70.9 
(66.4,75.2) 1,500 (500, 2,000) 
41,500 (32,000, 43,000) 
3.3 (1.7,5.5) 
Morocco 40.4 
(25.4,55.8) 12,500 (5,500, 21,000) 
263,000 (190,000, 328,000) 
4.7 (1.9,8.5) 
Occ. Palestinian 
Terr. 
31.2 
(26.3,36.2) NK 
NK 
NK 
Oman NK NK 15,500 (12,000, 17,500) NK 
Qatar NK NK 37,500 (29,500, 40,000) NK 
Saudi Arabia 58.3 
(53.7,63.0) NK 
106,000 (78,500, 190,000) 
NK 
South Sudan -- -- NK -- 
Sudan NK NK NK NK 
Syrian Arab Rep. 2.5 (0.9,4.3) NK 554,000 (245,000, 653,000) NK 
Tunisia 21.8 
(19.0,24.7) NK 
108,000 (25,000, 123,000) 
NK 
Turkey 33.7 
(30.7,36.7) NK 
492,000 (271,000, 763,000) 
NK 
United Arab 
Emirates NK NK 
131,000 (50,000, 159,000) 
NK 
Yemen NK NK 211,000 (143,000, 258,000) NK 
  
This article is protected by copyright. All rights reserved. 
 
Notes: 
-- Indicates no evidence located that injecting drug use was occurring in this country. 
NK Indicates no estimate of prevalence of that HCV was located, yet evidence of injecting drug 
use occurring in that country was identified. 
NR indicates that uncertainty was not estimated around the estimate. 
NG Indicates that no estimate of HCV amongst the general population was available. 
Italic font indicates that those uncertainty intervals were estimated in this review. 
PWID – people who inject drugs; HCV – Hepatitis C virus; UI - uncertainty interval (see methods for 
details of estimation).  
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Figure 1: Estimated prevalence of HCV viraemic infection among people with recent injecting drug 
use, by country 
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Figure 2: Estimated number of people with recent injecting drug use living with HCV viraemic 
infection, by country  
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Figure 3: Countries with the greatest total number of people with HCV viraemic infection among 
people with recent injecting drug use globally. The size of the bubble represents the total 
proportion of hepatitis C viraemic infections that among people with recent injecting drug use. An X 
indicates that data were not available to calculate the total proportion of viraemic HCV infections 
among people with recent injecting drug use.  
 
 
  
  
This article is protected by copyright. All rights reserved. 
Figure 4: Estimated proportion of people with recent injecting drug use among the total 
population with HCV viraemic infection, by country  
 
 
